The first case is an oncology patient, a 47 year old female with colorectal cancer. This lady presented herself while halfway through standard cancer treatment. Dr Anderson added many adjunct therapies as well as Low Dose Naltrexone and the patients tumour markers reduced for the first time.
The second case is about a 52-year old woman with Hashimoto’s - at the end of treatment this patient was stable enough that she actually went off the thyroid medication and she stayed on LDN, and she's been on LDN to this day.
The third case was a 29-year-old young woman with a lot of chronic infections that were positive on standard lab tests, autoimmune factors, and all of them poorly treated, not resolving. She had a positive test for Epstein-Barr mycoplasma. Dr Anderson describes how small changes made to her existing protocol and the addition of Low Dose Naltrexone was really the major therapeutic change. With the addition of LDN she suddenly started to have more effect from some of her other therapies.
Thank you for listening to this presentation. All past conference presentations can be found on our website: https://ldnresearchtrust.org/ldn-conferences